Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Explanation of Responses:

the new CEO, I mean, if he effected a merger/acq. that shot the share price to, oh let's just say, $2.00 per share. And the BOD, happy with that, we assume, signs him on as CEO.

He would then get 2.7 million options, struck at .40 each, which would make his profit 1.60 per share, or well north of 4 million dollars.

Now -- is he worth that? I would say no. So why so many options? Because, perhaps, merger talks are in the works that would move our share price considerably less?

Say he effects a merger that takes us to .80 per share, and they make him permanent CEO. Why, in just a few short months, he could cash in and make just over a cool million. Not a lot in So. Cal., I know...but the number of options they're throwing at him, contingent only on BOD approval (thank you Carlton, Helmut and Gloria...oh, and Nick, right, I forgot about him) seem very high. Disporportionately so.

Something fishy there?

JMHO

Share
New Message
Please login to post a reply